Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

New York ephedra bill

This article was originally published in The Tan Sheet

Executive Summary

Legislation to "ban the sale of supplements that contain ephedra in New York State except for the drugs under FDA supervision" recently introduced in state assembly. FDA's recent warning label proposal "fails to adequately address the risks" of ephedra, assemblywoman Audrey Pheffer says in March 19 comments to FDA urging national ban of the botanical. Bill A 6921, introduced March 12, would institute fines "of not more than $500 per violation" and statewide ban would apply to synthetic and natural forms sold as "Sea Grape, Yellow Horse, Country Mallow...Teamster's Tea and Yellow Astringent," among others, legislation states...

You may also be interested in...



NYC ephedra bill

Persons selling herbal ephedra products could be subject to criminal fines of up to $1,000 in addition to civil fines of up to $1,000 under legislation introduced in New York City Council April 30 by minority leader James Oddo (R-Staten Island) and others. Ban would exempt FDA-approved OTCs, certified alternative medical practitioners, although it would not allow practitioners to prescribe botanical for weight loss, energy/athletic performance. Bill was referred to Health Committee. Similar measure banning ephedra was introduced in state assembly March 12 and referred to Codes Committee April 1 (1"The Tan Sheet" April 14, 2003, In Brief)...

Roche/Genentech Keeps Commitment To External Cancer Innovation

Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.

US FDA Eases Changes For Certain Sterile Injectable Container Closure Materials

To mitigate pandemic disruption of component supply chains, the US FDA said it will downgrade some post-approval change categories for sterile drug container closure systems. The downgrade will cover drugs in shortage and those used to treat COVID-19.

Topics

UsernamePublicRestriction

Register

OM009724

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel